Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk’s Wegovy, in the first head-to-head clinical trial on the weekly injections. .

礼来公司周三表示，其减肥药 Zepbound 的减肥效果比其主要竞争对手诺和诺德更好的 Wegovy，在首次头对头临床试验中进行了每周注射。

The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in the phase three trial. Meanwhile, Wegovy helped people lose 13.7% of their weight, or about 33 pounds, on average after the same time period.

研究结果表明，Zepbound 可能是一种出色的减肥疗法，在第三阶段试验的 72 周后，它可帮助肥胖或超重患者平均减掉 20.2% 的体重，即大约 50 磅。与此同时，Wegovy 可帮助人们在同一时间段内平均减掉 13.7% 的体重，即大约 33 磅。

Eli Lilly said Zepbound provided a 47% higher relative weight reduction compared with Wegovy in the trial. The company added that more than 31% of people taking Zepbound lost at least a quarter of their body weight, compared to just about 16% of those on Wegovy who lost that much weight.

礼来公司表示，在试验中，Zepbound 的相对减重效果比 Wegovy 高出 47%。该公司还表示，服用 Zepbound 的人中，超过 31% 的人减掉了至少四分之一的体重，而服用 Wegovy 的人中，只有约 16% 的人减掉了这么多的体重。

Separate studies on the drugs, along with a recent head-to-head analysis of health records, have similarly implied that Zepbound outperforms Wegovy in terms of weight loss. A late-stage study on Zepbound showed that it helped patients lose more than 22% of their weight on average over 72 weeks, while a separate study on Wegovy showed that it led to 15% weight loss on average over 68 weeks.

针对这两款药物的独立研究以及近期对健康记录的直接对比分析同样表明，Zepbound 在减肥方面的表现优于 Wegovy。Zepbound 的一项后期研究表明，该药物在 72 周内帮助患者平均减重超过 22%，而 Wegovy 的另一项研究则表明，该药物在 68 周内平均减重 15% 。

But the Wednesday data appears to be the most concrete evidence of Zepbound’s edge, as the trial randomly assigned 751 patients to receive the maximum dose of either drug. The study specifically followed patients who were obese or overweight with at least one weight-related medical condition, not including diabetes.

但周三的数据似乎是 Zepbound 优势的最有力证据，因为该试验随机分配了 751 名患者接受最大剂量的任一药物。该研究专门跟踪了肥胖或超重且至少患有一种体重相关疾病（不包括糖尿病）的患者。

“Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice,” Dr. Leonard Glass, senior vice president of global medical affairs at Eli Lilly Cardiometabolic Health, said in a release.

礼来心脏代谢健康公司全球医疗事务高级副总裁伦纳德·格拉斯博士在新闻稿中表示：“鉴于人们对减肥药物的兴趣日益浓厚，我们进行了这项研究，以帮助医疗保健提供者和患者在治疗选择上做出明智的决定。”

Eli Lilly is still evaluating the results, which it plans to publish in a peer-reviewed journal and present at a medical meeting next year.

礼来公司仍在评估研究结果，并计划将其发表在同行评审期刊上，并在明年的医学会议上发表。

The most common side effects of both drugs were gastrointestinal and generally mild to moderate in severity.

这两种药物最常见的副作用是胃肠道反应，一般严重程度为轻度至中度。

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the booming weight loss drug market. Some analysts expect the space to be worth $150 billion a year by the early 2030s.

Zepbound 的减肥效果更佳，这对礼来来说是一个巨大的优势，礼来正在与诺和诺德争夺蓬勃发展的减肥药市场的更大份额。一些分析师预计，到 2030 年代初，该领域的年价值将达到 1500 亿美元。

Wegovy entered the market around two years before Zepbound, which won approval in the U.S. in late 2023. Still, some analysts believe Zepbound has a strong shot of becoming the best-selling drug of all time after more years on the market.

Wegovy 比 Zepbound 早两年左右进入市场，Zepbound 于 2023 年底在美国获得批准。不过，一些分析师认为，在上市几年后，Zepbound 很有可能成为有史以来最畅销的药物。

Data analytics firm GlobalData forecasts Zepbound will generate $27.2 billion in annual sales by 2030 and Wegovy will book $18.7 billion in annual revenue by the same year, according to data from November.

根据 11 月份的数据，数据分析公司 GlobalData预测，到 2030 年，Zepbound 的年销售额将达到 272 亿美元，而 Wegovy 的年收入将达到 187 亿美元。

Demand has far outstripped supply for Zepbound, Wegovy and their diabetes counterparts over the last year, forcing Eli Lilly and Novo Nordisk to pour billions into expanding their manufacturing capacity for the injections. Those efforts appear to be paying off, as the Food and Drug Administration now lists all doses of those treatments as “available” on its drug shortage database.

去年，Zepbound、Wegovy 及其糖尿病治疗药物的需求远远超过供应，迫使礼来和诺和诺德投入数十亿美元扩大注射剂的生产能力。这些努力似乎取得了成效，因为美国食品和药物管理局现在将这些治疗药物的所有剂量列为其药物短缺数据库中的 “可用”药物。

Still, some patients struggle to access the drugs due to the spotty insurance coverage of weight loss treatments in the U.S. Without insurance or other savings, Zepbound and Wegovy both cost around $1,000 per month.

然而，由于美国减肥治疗的保险覆盖范围不够广泛，一些患者仍难以获得这些药物。如果没有保险或其他储蓄，Zepbound 和 Wegovy 每月的费用都在 1,000 美元左右。

The treatments work differently.

治疗方法不同。

Zepbound tamps down appetite and regulates blood sugar by activating two gut hormones, called GIP and GLP-1. Wegovy activates GLP-1 but does not target GIP, which some researchers say may also affect how the body breaks down sugar and fat.

Zepbound 通过激活两种肠道激素（GIP 和 GLP-1）来抑制食欲并调节血糖。Wegovy 激活 GLP-1，但不针对 GIP，一些研究人员表示，GIP 也可能影响人体分解糖和脂肪的方式。